Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
This study is being done to evaluate the safety and effectiveness of alagebrium in subjects diagnosed with diastolic heart failure. The primary assessment for effectiveness is the assessment of exercise tolerance.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mobile, Alabama, United States
Anaheim, California, United States
Bakersfield, California, United States
La Jolla, California, United States
Roseville, California, United States
Jacksonville, Florida, United States
Miami, Florida, United States
St. Petersburg, Florida, United States
Start Date
March 1, 2008
Primary Completion Date
October 1, 2009
Completion Date
December 1, 2009
Last Updated
January 30, 2009
160
ESTIMATED participants
alagebrium
DRUG
placebo
DRUG
Lead Sponsor
Synvista Therapeutics, Inc
NCT05064709
NCT03338374
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00303498